Subtype
Female Reproductive System Neoplasm
CI-CAN-00000885Explore in graph →
Non-malignant1,633 active trials11 approved drugs139 evidence items
Loading cancer entity…
Subtype
CI-CAN-00000885Explore in graph →
Clinical trials
7,174 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00031759 | Imiquimod in Preventing Cervical Cancer in Women With Cervical Neoplasia | completed | Phase 2 | 57 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jul 13, 2016 | clinicaltrials |
| NCT01003938 | Topotecan With Erlotinib for Topotecan Pretreated Ovarian Cancer | terminated | Phase 2 | 6 | NYU Langone HealthOTHER | 1 | Jun 30, 2016 | clinicaltrials |
| NCT01283035 |
| A Phase II Study of Akt Inhibitor MK2206 in the Treatment of Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer |
| completed |
| Phase 2 |
| 6 |
| National Cancer Institute (NCI)NIH |
| 1 |
| Jun 24, 2016 |
| clinicaltrials |
| NCT00003852 | Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors | terminated | Phase 2 | 45 | UNICANCEROTHER | 1 | Jun 23, 2016 | clinicaltrials |
| NCT00327171 | Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer | completed | Phase 2 | 218 | SanofiINDUSTRY | 11 | Jun 7, 2016 | clinicaltrials |
| NCT01013324 | Study of XL147 (SAR245408) in Advanced or Recurrent Endometrial Carcinoma | completed | Phase 2 | 67 | SanofiINDUSTRY | 2 | Jun 3, 2016 | clinicaltrials |
| NCT00129727 | Carboplatin Taxol Avastin in Ovarian Cancer (OVCA) | completed | Phase 2 | 62 | Massachusetts General HospitalOTHER | 0 | Jun 1, 2016 | clinicaltrials |
| NCT00671606 | Hysteroscopic Lymphatic Mapping for Endometrial Cancer | terminated | Phase 2 | 5 | M.D. Anderson Cancer CenterOTHER | 1 | May 27, 2016 | clinicaltrials |
| NCT00664781 | Rucaparib(CO-338;Formally Called AG-014699 or PF-0136738) in Treating Patients With Locally Advanced or Metastatic Breast Cancer or Advanced Ovarian Cancer | completed | Phase 2 | 78 | Cancer Research UKOTHER | 1 | May 24, 2016 | clinicaltrials |
| NCT02781155 | Limiting Chemotherapy Side Effects by Using Moxa | unknown | Phase 1 / Phase 2 | 25 | East and North Hertfordshire NHS TrustOTHER_GOV | 1 | May 24, 2016 | clinicaltrials |
| NCT00002558 | Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors | completed | Phase 1 / Phase 2 | 108 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 23, 2016 | clinicaltrials |
| NCT00423852 | Paclitaxel, Ifosfamide, and Carboplatin Followed By Autologous Stem Cell Transplant in Treating Patients With Germ Cell Tumors That Did Not Respond to Cisplatin | completed | Phase 1 / Phase 2 | 26 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 18, 2016 | clinicaltrials |
| NCT01256424 | Dose-finding Study of Hexaminolevulinate (HAL) Photodynamic Therapy (PDT) to Treat Cervical Neoplasia | completed | Phase 2 | 262 | PhotocureINDUSTRY | 2 | May 16, 2016 | clinicaltrials |
| NCT02501278 | A Phase II Clinical Trial of Chemo-radiotherapy in Combination With INO-3112 in Patients With Locally Advanced Cervical Cancer | withdrawn | Phase 2 | 0 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 1 | May 13, 2016 | clinicaltrials |
| NCT01447706 | A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers | completed | Phase 2 | 223 | Merrimack PharmaceuticalsINDUSTRY | 1 | May 12, 2016 | clinicaltrials |
| NCT00634894 | Femara (Letrozole) Versus Placebo for Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 20, 2016 | clinicaltrials |
| NCT02195089 | Efficacy and Safety Study of BLS_ILB_E710c for the Fertile Women With Cervical Intraepithelial Neoplasia(CIN3) | completed | Phase 1 / Phase 2 | 19 | BioLeaders CorporationINDUSTRY | 1 | Apr 19, 2016 | clinicaltrials |
| NCT00671788 | A Phase II Evaluation of Dasatinib (Sprycel®, NSC #732517) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma | completed | Phase 2 | 35 | Gynecologic Oncology GroupNETWORK | 1 | Apr 15, 2016 | clinicaltrials |
| NCT02479178 | A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck(iNSITE2) | terminated | Phase 2 | 73 | BIND TherapeuticsINDUSTRY | 2 | Apr 14, 2016 | clinicaltrials |
| NCT02324595 | Minimally Invasive Interval Debulking Surgery in Ovarian Neoplasm: a Feasibility Study(MISSION) | completed | Phase 2 | 30 | Catholic University of the Sacred HeartOTHER | 1 | Apr 13, 2016 | clinicaltrials |
| NCT00064025 | Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus | completed | Phase 2 | 75 | Gynecologic Oncology GroupNETWORK | 1 | Apr 11, 2016 | clinicaltrials |
| NCT00170664 | Taxol/ Carboplatin as First Line Therapy in Patients With Epithelial Ovarian Cancer | completed | Phase 2 | 129 | North Eastern German Society of Gynaecological OncologyOTHER | 1 | Mar 25, 2016 | clinicaltrials |
| NCT01033123 | A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Sensitive Recurrent Ovarian Cancer | completed | Phase 2 | 41 | SanofiINDUSTRY | 1 | Mar 17, 2016 | clinicaltrials |
| NCT01033292 | A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Resistant Recurrent Ovarian Cancer | completed | Phase 2 | 43 | SanofiINDUSTRY | 1 | Mar 17, 2016 | clinicaltrials |
| NCT00003334 | Combination Chemotherapy in Treating Patients With Endometrial Cancer, Fallopian Tube Cancer, or Sarcoma of the Female Reproductive Tract | completed | Phase 2 | — | NYU Langone HealthOTHER | 1 | Mar 11, 2016 | clinicaltrials |
| NCT00182767 | Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer | completed | Phase 1 / Phase 2 | 45 | National Cancer Institute (NCI)NIH | 1 | Mar 10, 2016 | clinicaltrials |
| NCT02705612 | Phase II Clinical Trial of Concurrent Chemoradiotherapy Combined Nimotuzumab for Stage IIB-IVA Cervical Cancer | unknown | Phase 2 | 60 | Air Force Military Medical University, ChinaOTHER | 1 | Mar 10, 2016 | clinicaltrials |
| NCT00526799 | Sorafenib + Topotecan for Platinum-Resistant Recurrent Ovarian Cancer | terminated | Phase 1 / Phase 2 | 30 | Daniela Matei, MDOTHER | 1 | Mar 3, 2016 | clinicaltrials |
| NCT00522301 | Sorafenib in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in at Least the Second Remission | terminated | Phase 2 | 6 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 29, 2016 | clinicaltrials |
| NCT01460979 | Efficacy,Tolerability,Safety of Temsirolimus in Women With Platinum-refractory Ovarian Carcinoma or Advanced Endometrial Carcinoma | completed | Phase 2 | 47 | AGO Study GroupOTHER | 1 | Feb 29, 2016 | clinicaltrials |
| NCT00123773 | Study of F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Known or Suspected Cancers of Low Incidence | completed | Phase 2 | 1,075 | AHS Cancer Control AlbertaOTHER | 1 | Feb 26, 2016 | clinicaltrials |
| NCT01709487 | Feasibility Study of HIPEC for Patients With Stage III or Only Pleural Stage IV Ovarian Carcinoma in First Line Therapy | completed | Phase 1 / Phase 2 | 19 | Jules Bordet InstituteOTHER | 1 | Feb 24, 2016 | clinicaltrials |
| NCT00154089 | A Pilot Study of EM-1421 for the Treatment of Cervical Intraepithelial Neoplasia | completed | Phase 1 / Phase 2 | 8 | Erimos PharmaceuticalsINDUSTRY | 1 | Feb 23, 2016 | clinicaltrials |
| NCT02487693 | Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Ovarian Carcinoma | active not recruiting | Phase 2 | 50 | The First People's Hospital of ChangzhouOTHER | 0 | Feb 23, 2016 | clinicaltrials |
| NCT02490748 | Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cervical Cancer | active not recruiting | Phase 2 | 10 | The First People's Hospital of ChangzhouOTHER | 0 | Feb 23, 2016 | clinicaltrials |
| NCT00587964 | Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases | completed | Phase 2 | 51 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 22, 2016 | clinicaltrials |
| NCT00216112 | Imatinib Mesylate in Combination With Docetaxel for Advanced, Platinum-Refractory Ovarian Cancer | completed | Phase 2 | 23 | Daniela Matei, MDOTHER | 1 | Feb 19, 2016 | clinicaltrials |
| NCT01426880 | Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer(GeparSixto) | completed | Phase 2 / Phase 3 | 595 | GBG Forschungs GmbHOTHER | 1 | Feb 15, 2016 | clinicaltrials |
| NCT00284427 | Safety of Antioxidants During GYN Cancer Care | completed | Phase 2 | 25 | Jeanne Drisko, MD, CNS, FACNOTHER | 0 | Feb 10, 2016 | clinicaltrials |
| NCT01238770 | Phase I/II Study of Pazopanib and Cyclophosphamide in Patients With Platinum-resistant Recurrent Ovarian Cancer | completed | Phase 1 / Phase 2 | 10 | Priv.-Doz. Dr. med. Joachim RomOTHER | 1 | Feb 10, 2016 | clinicaltrials |
| NCT00152828 | Celebrex - Cervix: Celecoxib in the Treatment of Patients With Locally Advanced Carcinoma of the Cervix | completed | Phase 1 / Phase 2 | 31 | University Health Network, TorontoOTHER | 1 | Feb 9, 2016 | clinicaltrials |
| NCT00188578 | Intensity Modulated Radiation Therapy - Gyne Cancer (GY03.2) | completed | Phase 1 / Phase 2 | 12 | University Health Network, TorontoOTHER | 1 | Feb 9, 2016 | clinicaltrials |
| NCT01826045 | Efficacy and Safety Study of PGA (Poly-gamma Glutamic Acid) for Cervical Intraepithelial Neoplasia(PGA) | completed | Phase 2 | 200 | BioLeaders CorporationINDUSTRY | 1 | Jan 29, 2016 | clinicaltrials |
| NCT01637532 | Feasibility of the Combination of Chemotherapy (Carbo/Caelyx or Carbo/Doxorubicin) With Tocilizumab (mAb IL-6R) and Peg-Intron in Patients With Recurrent Ovarian Cancer(PITCH) | completed | Phase 1 / Phase 2 | 21 | Leiden University Medical CenterOTHER | 1 | Jan 26, 2016 | clinicaltrials |
| NCT00474994 | Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas | completed | Phase 2 | 53 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 20, 2016 | clinicaltrials |
| NCT00588237 | Intravenous and Intraperitoneal Paclitaxel, Intraperitoneal Cisplatin, and Intravenous Bevacizumab for the Initial Treatment of Optimal Stage II or III Ovarian, Primary Peritoneal, and Fallopian Tube Cancer | completed | Phase 2 | 42 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 20, 2016 | clinicaltrials |
| NCT00401674 | MITO-5: Weekly Carboplatin and Paclitaxel as First Line Chemotherapy for Elderly Patients With Ovarian Cancer(MITO-5) | completed | Phase 2 | 26 | National Cancer Institute, NaplesOTHER | 1 | Jan 14, 2016 | clinicaltrials |
| NCT00403429 | MITO-6: Capecitabine in Platinum Resistant Ovarian Cancer | completed | Phase 2 | 36 | National Cancer Institute, NaplesOTHER | 1 | Jan 14, 2016 | clinicaltrials |
| NCT00718523 | Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer | terminated | Phase 2 | 170 | Translational Research in OncologyOTHER | 8 | Jan 12, 2016 | clinicaltrials |
| NCT00719212 | Study of AMG 479 as Second Line Therapy in Patients With Recurrent Platinum-sensitive Ovarian Cancer | completed | Phase 2 | 61 | Translational Research in OncologyOTHER | 7 | Jan 11, 2016 | clinicaltrials |
Data updated 24 days agoSource updated Jul 13, 2016source: clinicaltrials